Changes in healthcare utilization and costs associated with sildenafil therapy for pulmonary arterial hypertension: a retrospective cohort study

@inproceedings{Berger2012ChangesIH,
  title={Changes in healthcare utilization and costs associated with sildenafil therapy for pulmonary arterial hypertension: a retrospective cohort study},
  author={Ariel Berger and John S Edelsberg and Simon Teal and Marko Andrew Mychaskiw and Gerry Ann Oster},
  booktitle={BMC pulmonary medicine},
  year={2012}
}
BACKGROUND Little is known concerning the degree to which initiation of sildenafil for pulmonary arterial hypertension (PAH) impacts patterns of healthcare utilization and costs. METHODS Using a large US health insurance claims database, we identified all patients with evidence of PAH (ICD-9-CM diagnosis codes 416.0, 416.8) who received sildenafil between 1/1/2005 and 9/30/2008. Date of the first-noted prescription for sildenafil was designated the "index date," and claims data were compiled… CONTINUE READING
BETA

Figures, Tables, and Topics from this paper.

Citations

Publications citing this paper.
SHOWING 1-9 OF 9 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 22 REFERENCES

Similar Papers

Loading similar papers…